Worth reading
71In focus
Scored from 4 of 5 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
5000000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 27th Series Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension Clauses)
Who receives how much
Shares delivered during the applicable month: 5,000,000 shares (new shares: 5,000,000 shares; transferred treasury shares: -)
EVO FUND (allottee of the 27th Series of Stock Acquisition Rights)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+0.39%Rate of increase
1,274,171,340 shares1,279,913,624Shares
Exercise ratio subject to exercise restrictions: 0.39% (5,000,000 shares / 1,274,171,340 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price in April 2026: ¥328 to ¥345. The terms provide for adjustment on each trading day to the closing price on the immediately preceding trading day, or the minimum exercise price if that closing price is below the minimum exercise price. The specific minimum exercise price is not disclosed.
Exercise period
Commencing 16 April 2026 (end date not disclosed)
Number of Stock Acquisition Rights
Total number issued: 1,000,000 rights. Number exercised during the applicable month: 50,000 rights. Number remaining unexercised at the end of the applicable month: 950,000 rights.
Basis for determining the amount to be paid
The exercise price is adjusted to the closing price on the immediately preceding trading day, or the minimum exercise price if that closing price is below the minimum exercise price. The initial adjustment was made on 17 April 2026. The discount rate and premium rate are not disclosed.
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. Whether an independent third-party opinion was obtained and shareholder approval was sought is not disclosed.
Most recent equity financing
Announced on 16 March 2026: issuance through a third-party allotment of the 27th Series of Stock Acquisition Rights (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension provisions) and execution of a purchase agreement for the Stock Acquisition Rights. The amount is not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 27th Series Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension Clauses) |
| Number of shares to be issued or disposed of | Shares delivered during the applicable month: 5,000,000 shares (new shares: 5,000,000 shares; transferred treasury shares: -) |
| Intended allottee | EVO FUND (allottee of the 27th Series of Stock Acquisition Rights) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.39% (5,000,000 shares / 1,274,171,340 shares) |
| Total number of issued shares | 1,274,171,340 shares (number of listed shares as of the payment date for the issuance) → 1,279,913,624 shares (number of issued common shares as of 30 April 2026) |
| Basis for determining the amount to be paid | The exercise price is adjusted to the closing price on the immediately preceding trading day, or the minimum exercise price if that closing price is below the minimum exercise price. The initial adjustment was made on 17 April 2026. The discount rate and premium rate are not disclosed. |
| Exercise price | Exercise price in April 2026: ¥328 to ¥345. The terms provide for adjustment on each trading day to the closing price on the immediately preceding trading day, or the minimum exercise price if that closing price is below the minimum exercise price. The specific minimum exercise price is not disclosed. |
| Exercise period | Commencing 16 April 2026 (end date not disclosed) |
| Number of Stock Acquisition Rights | Total number issued: 1,000,000 rights. Number exercised during the applicable month: 50,000 rights. Number remaining unexercised at the end of the applicable month: 950,000 rights. |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. Whether an independent third-party opinion was obtained and shareholder approval was sought is not disclosed. |
| Most recent equity financing | Announced on 16 March 2026: issuance through a third-party allotment of the 27th Series of Stock Acquisition Rights (with Exercise Price Adjustment, mNAV, Minimum Exercise Price Adjustment and Exercise Suspension provisions) and execution of a purchase agreement for the Stock Acquisition Rights. The amount is not disclosed. |
Items this document does not state (17)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the 27th Series of Stock Acquisition Rights in April 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.